Literature DB >> 12859292

Intravenous immunoglobulin in the preparation of thymectomy for myasthenia gravis.

C-S Huang1, H-S Hsu, K-P Kao, M-H Huang, B-S Huang.   

Abstract

OBJECTIVES: A clinical trial including six patients was conducted to assess the effect of intravenous immunoglobulin (IVIg) in the preparation of thymectomy for patients with myasthenia gravis (MG).
MATERIAL AND METHODS: Six consecutive patients of type IIB MG treated with IVIg at a dose 0.4 g/kg daily for 5 days before thymectomy were enrolled in this study.
RESULTS: All patients responded positively to this treatment. Improvement began to occur 1-9 days after starting the injection (mean 3.33 days), and reached a maximum in 3-19 days (mean 6.50 days). Thymectomy was performed 9-13 days (mean 11.20 days) after starting the injection in five of the six patients with uneventful post-operative courses.
CONCLUSION: IVIg might be an alternative to plasmapheresis (PE) in the prethymectomy preparation of MG patients, and thymectomy should be performed within 2 weeks after IVIg treatment to minimize the perioperative complications. Controlled trial vs PE enrolling more patients is needed to assess the significance of the IVIg in the preparation of thymectomy for patients of MG.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12859292     DOI: 10.1034/j.1600-0404.2003.00131.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  6 in total

1.  Intravenous immunoglobulin for preparing myasthenia gravis patients for thymectomy and other surgical procedures preventing myasthenic crisis.

Authors:  J Gamez
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 2.  Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014.

Authors:  Yoshihisa Kadota; Hirotoshi Horio; Takeshi Mori; Noriyoshi Sawabata; Taichiro Goto; Shin-ichi Yamashita; Takeshi Nagayasu; Akinori Iwasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-01-22

3.  Autoimmune Myasthenia Gravis: Recommendations for Treatment and Immunologic Modulation.

Authors:  Vern C Juel; Janice M Massey
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.972

Review 4.  Myasthenia gravis.

Authors:  Vern C Juel; Janice M Massey
Journal:  Orphanet J Rare Dis       Date:  2007-11-06       Impact factor: 4.123

5.  Intravenous immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis.

Authors:  Josep Gamez; María Salvadó; Francesc Carmona; Miriam de Nadal; Laura Romero; Daniel Ruiz; Alberto Jáuregui; Olga Martínez; Javier Pérez; Pilar Suñé; María Deu
Journal:  Ther Adv Neurol Disord       Date:  2019-07-17       Impact factor: 6.570

6.  Myasthenic crisis and late deep vein thrombosis following thymectomy in a patient with myasthenia gravis: A case report.

Authors:  Cheng-Yuan Lin; Wei-Cheng Liu; Min-Hsien Chiang; I-Ting Tsai; Jen-Yin Chen; Wan-Jung Cheng; Chun-Ning Ho; Shu-Wei Liao; Chin-Chen Chu; Cheuk-Kwan Sun; Kuo-Chuan Hung
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.